The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction

The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction

The study aims to evaluate the effect of trimetazidine in reducing reperfusion arrhythmias in patients with acute myocardial infarction after successful thrombolysis. A total of 169 patients were included in the study, 83 of whom received trimetazidine orally at an initial dose of 60 mg followed by...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology Vol. 55; no. 2; pp. 137 - 142
Main Authors: Papadopoulos, C.L., Kanonidis, I.E., Kotridis, P.S., Papayannis, I.L., Savatis, S.C., Missopoulou-Kokka, A.I., Nikolaidis, N.K., Koukoulekidis, G.N., Sakadamis, G.C.
Format: Journal Article
Language:English
Published: Shannon Elsevier Ireland Ltd 26-07-1996
Elsevier Science
Subjects:
Acute myocardial infarction
Antianginal agents. Coronary vasodilator agents
Arrhythmias, Cardiac - prevention & control
Biological and medical sciences
Cardiovascular system
Chi-Square Distribution
Confidence Intervals
Female
Free Radical Scavengers - therapeutic use
Free radicals
Humans
Male
Medical sciences
Middle Aged
Myocardial Infarction - complications
Myocardial Infarction - therapy
Myocardial Reperfusion - adverse effects
Odds Ratio
Pharmacology. Drug treatments
Severity of Illness Index
Thrombolysis
Thrombolytic Therapy - adverse effects
Trimetazidine - therapeutic use
Acute myocardial infarction
Thrombolysis
Free radicals
Human
Intravenous administration
Infarct
Arrhythmia
Coronary vasodilator agent
Oral administration
Cardiovascular disease
Controlled therapeutic trial
Coronary heart disease
Myocardial disease
Prevention
Chemotherapy
Reperfusion
Heart disease
Myocardium
Adult
Piperazine derivatives
Fibrinolytic
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The study aims to evaluate the effect of trimetazidine in reducing reperfusion arrhythmias in patients with acute myocardial infarction after successful thrombolysis. A total of 169 patients were included in the study, 83 of whom received trimetazidine orally at an initial dose of 60 mg followed by 20 mg tid for 5 days. These patients formed the study group (group T) while the remaining 86, the control group (group C). Successful thrombolysis by clinical and electrocardiographic criteria was observed in 53 patients of group T and in 55 patients of group C. Reperfusion arrhythmias were observed in 16 patients in group T (30.1%) and in 31 in group C (56.3%). This difference was statistically significant. Serious ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation) were observed in 1 patient of group T (1.8%) and in 6 patients of group C (10.9%). This difference was also statistically significant. It is concluded that trimetazidine administration can reduce the rate of reperfusion arrhythmias. This conclusion should be confirmed by larger clinical trials in order to give to the clinical results a stronger statistical power.
ISSN:0167-5273
1874-1754
DOI:10.1016/0167-5273(96)02678-2